4/17
06:01 am
dsnky
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions [Yahoo! Finance]
Low
Report
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions [Yahoo! Finance]
4/17
12:48 am
dsnky
Merck's Priority Review Cancer Drug Adds To Undervalued Growth Story [Yahoo! Finance]
Low
Report
Merck's Priority Review Cancer Drug Adds To Undervalued Growth Story [Yahoo! Finance]
4/16
08:11 pm
dsnky
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies [Yahoo! Finance]
Low
Report
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies [Yahoo! Finance]
4/16
05:48 am
dsnky
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies
Low
Report
Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies
4/15
09:54 am
dsnky
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase [Yahoo! Finance]
Low
Report
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase [Yahoo! Finance]
4/15
09:23 am
dsnky
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase [TheStreet.com]
Medium
Report
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase [TheStreet.com]
4/15
09:04 am
dsnky
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase
Medium
Report
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase
4/14
07:36 am
dsnky
4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program [Yahoo! Finance]
Low
Report
4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program [Yahoo! Finance]
4/8
02:28 am
dsnky
ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation [Yahoo! Finance]
Low
Report
ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation [Yahoo! Finance]
4/1
03:34 pm
dsnky
Can Tempus AI's (TEM) ALERT Trial Quietly Redefine Its Real-World Data Advantage in Cardiology? [Yahoo! Finance]
Low
Report
Can Tempus AI's (TEM) ALERT Trial Quietly Redefine Its Real-World Data Advantage in Cardiology? [Yahoo! Finance]
4/1
09:03 am
dsnky
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo [Seeking Alpha]
Low
Report
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo [Seeking Alpha]
3/31
09:27 pm
dsnky
Tempus AI Daiichi Sankyo Tie Up Highlights Precision Oncology Opportunity [Yahoo! Finance]
Medium
Report
Tempus AI Daiichi Sankyo Tie Up Highlights Precision Oncology Opportunity [Yahoo! Finance]
3/28
03:12 am
dsnky
Daiichi Sankyo's ADC Alliances Test Valuation Gap In Oncology Strategy [Yahoo! Finance]
Low
Report
Daiichi Sankyo's ADC Alliances Test Valuation Gap In Oncology Strategy [Yahoo! Finance]
3/25
08:30 am
dsnky
Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program
Low
Report
Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program
3/18
11:21 am
dsnky
Is Now The Right Time To Reassess Daiichi Sankyo (TSE:4568) After Recent Share Price Weakness? [Yahoo! Finance]
Low
Report
Is Now The Right Time To Reassess Daiichi Sankyo (TSE:4568) After Recent Share Price Weakness? [Yahoo! Finance]
3/18
08:30 am
dsnky
Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms [Yahoo! Finance]
Low
Report
Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms [Yahoo! Finance]
3/17
09:05 am
dsnky
Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs [Yahoo! Finance]
Medium
Report
Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs [Yahoo! Finance]
3/16
02:32 pm
dsnky
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp [Yahoo! Finance]
Low
Report
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp [Yahoo! Finance]
3/12
04:14 am
dsnky
Allegro's osteoarthritis hydrogel resolves lameness in animal study [Yahoo! Finance]
Low
Report
Allegro's osteoarthritis hydrogel resolves lameness in animal study [Yahoo! Finance]
3/9
10:36 pm
dsnky
AstraZeneca Oncology Updates Prompt Fresh Look At Valuation And Growth Potential [Yahoo! Finance]
Low
Report
AstraZeneca Oncology Updates Prompt Fresh Look At Valuation And Growth Potential [Yahoo! Finance]
3/9
07:16 am
dsnky
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer [Yahoo! Finance]
Low
Report
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer [Yahoo! Finance]
3/9
02:46 am
dsnky
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer [Yahoo! Finance]
Low
Report
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer [Yahoo! Finance]
3/9
02:30 am
dsnky
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Low
Report
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
3/5
07:52 am
dsnky
Daiichi and GAIA join forces to commercialise digital cardiovascular therapy [Yahoo! Finance]
Low
Report
Daiichi and GAIA join forces to commercialise digital cardiovascular therapy [Yahoo! Finance]
3/5
02:15 am
dsnky
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. [Yahoo! Finance]
Low
Report
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. [Yahoo! Finance]